Faculty, Staff and Student Publications

Publication Date

4-1-2024

Journal

Future Oncology

DOI

10.2217/fon-2022-1249

PMID

37815847

PMCID

PMC12510239

PubMedCentral® Posted Date

4-8-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.

Keywords

Humans, Cetuximab, Proto-Oncogene Proteins B-raf, Mutation, Colorectal Neoplasms, Colonic Neoplasms, Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic, Antibodies, Monoclonal, Humanized, Neoplastic Syndromes, Hereditary, Sulfonamides, Brain Neoplasms, Carbamates

Comments

Trial registration: ClinicalTrials.gov NCT05217446.

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.